LS: Next Growth Curve
Biopharmaceutical companies are operating in an increasingly fragmented environment, with global dynamics shifting rapidly. Developed markets that for long offered predictable growth are now slowing, reflecting not only the stabilisation typical of mature healthcare systems but also mounting pricing and budgetary pressures.
In the US and Western Europe, healthcare spend as a share of GDP is pressing affordability limits, driving payers to extract savings across drug budgets to create headroom for next‑generation biologics and cell and gene therapies.
At the same time, momentum is shifting to emerging markets—particularly across the Middle East and Africa—where 2025 delivered the largest global pharma expansion, with IQVIA noting countries such as Saudi Arabia helped drive 18% year‑on‑year regional growth. Through 2030, “pharmerging” markets are projected to add $121 billion in medicine spending. Capturing this growth requires new playbooks: align portfolios to affordability realities; localise manufacturing to win tenders and accelerate access; and modernise distribution and digital channels—moves already reshaping strategies in Saudi Arabia, Egypt, and North Africa.
In this analysis, our Healthcare & Life Sciences team examines where growth is concentrating, what is changing in access and infrastructure, and how localisation, distribution upgrades, and digital channels can unlock scale. We've synthesised regional policy shifts, tender dynamics, and manufacturing advances into five pragmatic actions to help biopharma leaders compete and win across developing markets.
The Next Growth Curve
How Biopharma Can Win in Developing Markets
Biopharma’s next growth curve is unfolding across the Middle East and Africa—where 2025 delivered the world’s biggest pharma expansion and “pharmerging” markets are set to add $121B in medicine spending by 2030. Yet success hinges on solving affordability and access, localizing manufacturing to win tenders, and modernizing distribution and digital channels. See how Saudi Arabia’s push toward 70% local spend, Egypt’s export ambitions, and advances in modular biomanufacturing are reshaping go-to-market—and the five moves that will separate winners from the pack.
Emerging markets are redefining biopharma’s growth trajectory—but leadership will hinge on disciplined execution. Companies that focus portfolios on cost-effective innovation, localise to win tenders and accelerate access, upgrade specialty distribution, digitise patient pathways, and build regional hubs will be best positioned to convert headroom into durable share gains.
The window is open: demand is expanding, policy is enabling, and technology is lowering the barriers to scale. The next step is action—prioritise the five moves, sequence them market-by-market, and mobilise cross-functional teams to deliver results on the ground.
Get in touch with our experts
Our team leverages its local and global presence to support companies, creditors, shareholders and other stakeholders in their financial restructuring and debt renegotiation processes, counting with a team of experts in complex capital structure cases.
Our financial restructuring services include:
- Debtor advisory
- Debt renegotiation
- Structuring vehicles aimed at restructuring liabilities or at recovering and selling selected assets
- Preparation and implementation of judicial or extrajudicial restructurings
- Debt-to-Equity conversion
Our team has extensive experience in mergers, acquisitions and divestments for different industries, along with the sale of assets and divestments realized in the scope of restructuring cases. Our deep network and comprehensive knowledge of the industries and stakeholders allow us to identify and engage the investors that best suit the situation.
Our goal is to assist companies, lenders and potential investors in mergers and acquisitions that require complex structuring or involve financially distressed assets. The strategic and tactical knowledge of M&A, combined with the support of other A&M practices on operational performance improvement, capital projects advisory, and financial and tax due diligence, differentiate us in:
- Identification and evaluation of acquisition targets
- Valuation and transaction pricing
- Assessment of transaction terms and corporate structures
- Negotiation and conclusion of the transaction
Mergers and Acquisitions
Our team has extensive experience in mergers, acquisitions and divestments for different industries, along with the sale of assets and divestments realized in the scope of restructuring cases. Our deep network and comprehensive knowledge of the industries and stakeholders allow us to identify and engage the investors that best suit the situation.
25
Mergers
55
Acquisitions
Our Solutions
Financial Restructuring
Our team leverages its local and global presence to support companies, creditors, shareholders and other stakeholders in their financial restructuring and debt renegotiation processes, counting with a team of experts in complex capital structure cases.
Our financial restructuring services include:
- Debtor advisory
- Debt renegotiation
- Structuring vehicles aimed at restructuring liabilities or at recovering and selling selected assets
- Preparation and implementation of judicial or extrajudicial restructurings
- Debt-to-Equity conversion
Mergers and Acquisitions
Our team has extensive experience in mergers, acquisitions and divestments for different industries, along with the sale of assets and divestments realized in the scope of restructuring cases. Our deep network and comprehensive knowledge of the industries and stakeholders allow us to identify and engage the investors that best suit the situation.
Our goal is to assist companies, lenders and potential investors in mergers and acquisitions that require complex structuring or involve financially distressed assets. The strategic and tactical knowledge of M&A, combined with the support of other A&M practices on operational performance improvement, capital projects advisory, and financial and tax due diligence, differentiate us in:
- Identification and evaluation of acquisition targets
- Valuation and transaction pricing
- Assessment of transaction terms and corporate structures
- Negotiation and conclusion of the transaction
Carousel with Icon, Number and Description
Carousel with Icon, Number and Description Text
25
Column 1
Text 1
50
stats 2
stats 2 Text
75
stats 3
stats 3 Text
Lorem Ipsum is simply dummy text of the printing
Why do we use it?
It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using 'Content here, content here', making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for 'lorem ipsum' will uncover many web sites still in their infancy. Various versions have evolved over the years, sometimes by accident, sometimes on purpose (injected humour and the like).
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC,
Jon Doe
Managing Director
Our IT Due Diligence service supports both private equity and corporate clients in evaluating the technology posture of a target company during the transaction lifecycle. Whether on the buy side or sell side, our aim is to identify critical technology risks, validate investment assumptions, and highlight opportunities to drive value creation post-deal. We combine deep technical expertise with commercial insight to ensure our clients are equipped with a clear, actionable view of IT’s role in the asset’s performance and scalability.
Our IT M&A Carve-Out and Integration offering is designed to support clients through the complex lifecycle of mergers, acquisitions, and divestitures, from due diligence through TSA (Transition Services Agreement) exit. We partner with both private equity and corporate clients—on the buy side and sell side—to provide expert guidance at each critical milestone: pre-sign, sign-to-close, Day 1 readiness, and post-Day 1 execution. Our consultants identify and manage key IT risks, design separation or integration strategies, and ensure smooth transitions with minimal disruption to operations.
Our Tech Cost Optimization service is designed to help private equity and corporate clients reduce recurring costs across business and IT functions, without compromising performance or growth potential. We work closely with stakeholders to identify areas where technology can either replace inefficient processes or where current IT spend can be streamlined for greater impact. Whether the goal is to enhance EBITDA pre-exit, improve operating margins, or reinvest savings into innovation, our approach is grounded in measurable outcomes and strategic value creation.
In an era where digital transformation is no longer optional, technology modernization helps businesses to unlock their full potential. By leveraging forward-looking technology and a strategic approach, we enable organizations to achieve their business strategy, streamline operations, drive sustainable growth and modernize the technology landscape.
Quote Image Carousel
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy
Roden Robert
MD
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy
Ellis Nicola
MD
